Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

Gil Klinger; Yair Morad; Carol A. Westall; Carl Laskin; Karen A. Spitzer; Gideon Koren; Shinya Ito; Raymond J. Buncic

doi:10.1016/S0140-6736(01)06004-4

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

Gil Klinger
, Yair Morad
, Carol A. Westall
, Carl Laskin
, Karen A. Spitzer
, Gideon Koren
, Shinya Ito
, Raymond J. Buncic

Research output: Contribution to journal › Article › peer-review

120 Scopus citations

Abstract

Chronic use of chloroquine and hydroxychloroquine in the treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugs during pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine. The mean duration of gestational exposure was 7.2 months. No ophthalmic abnormality was detected in these children. Therapeutic use of these drugs during pregnancy may not pose a significant risk of ocular toxicity to offspring.

Original language	English
Pages (from-to)	813-814
Number of pages	2
Journal	The Lancet
Volume	358
Issue number	9284
DOIs	https://doi.org/10.1016/S0140-6736(01)06004-4
State	Published - 8 Sep 2001
Externally published	Yes

Access to Document

10.1016/S0140-6736(01)06004-4

Cite this

@article{230aaae5d6874e509452713f8dd4d5f6,

title = "Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases",

abstract = "Chronic use of chloroquine and hydroxychloroquine in the treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugs during pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine. The mean duration of gestational exposure was 7.2 months. No ophthalmic abnormality was detected in these children. Therapeutic use of these drugs during pregnancy may not pose a significant risk of ocular toxicity to offspring.",

author = "Gil Klinger and Yair Morad and Westall, \{Carol A.\} and Carl Laskin and Spitzer, \{Karen A.\} and Gideon Koren and Shinya Ito and Buncic, \{Raymond J.\}",

note = "Funding Information: G Klinger received a fellowship award from the Research Institute, Hospital for Sick Children, Toronto, Canada. G Koren was supported by Senior Scientists Award from the Canadian Institute of Health Research. S Ito was supported by Career Award in Health Sciences from the Canadian Institute of Health Research and the Health Research Foundation. This study was supported in part by the Motherisk Research fund, and by Breastfeeding Programme fund, Hospital for Sick Children, Toronto.",

year = "2001",

month = sep,

day = "8",

doi = "10.1016/S0140-6736(01)06004-4",

language = "אנגלית",

volume = "358",

pages = "813--814",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9284",

}

TY - JOUR

T1 - Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

AU - Klinger, Gil

AU - Morad, Yair

AU - Westall, Carol A.

AU - Laskin, Carl

AU - Spitzer, Karen A.

AU - Koren, Gideon

AU - Ito, Shinya

AU - Buncic, Raymond J.

N1 - Funding Information: G Klinger received a fellowship award from the Research Institute, Hospital for Sick Children, Toronto, Canada. G Koren was supported by Senior Scientists Award from the Canadian Institute of Health Research. S Ito was supported by Career Award in Health Sciences from the Canadian Institute of Health Research and the Health Research Foundation. This study was supported in part by the Motherisk Research fund, and by Breastfeeding Programme fund, Hospital for Sick Children, Toronto.

PY - 2001/9/8

Y1 - 2001/9/8

N2 - Chronic use of chloroquine and hydroxychloroquine in the treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugs during pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine. The mean duration of gestational exposure was 7.2 months. No ophthalmic abnormality was detected in these children. Therapeutic use of these drugs during pregnancy may not pose a significant risk of ocular toxicity to offspring.

AB - Chronic use of chloroquine and hydroxychloroquine in the treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugs during pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine. The mean duration of gestational exposure was 7.2 months. No ophthalmic abnormality was detected in these children. Therapeutic use of these drugs during pregnancy may not pose a significant risk of ocular toxicity to offspring.

UR - https://www.scopus.com/pages/publications/0035828399

U2 - 10.1016/S0140-6736(01)06004-4

DO - 10.1016/S0140-6736(01)06004-4

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 11564493

AN - SCOPUS:0035828399

SN - 0140-6736

VL - 358

SP - 813

EP - 814

JO - The Lancet

JF - The Lancet

IS - 9284

ER -

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

Abstract

Access to Document

Other files and links

Fingerprint

Cite this